Telix Pharmaceuticals Logo
Telix Pharmaceuticals Logo
  • Our Company
    • Our Company
    • Purpose, Mission & Values
    • Board & Management
    • Our Technology
    • Sustainability
  • Our Portfolio
    • Our Portfolio
    • Disease Areas
      • Prostate Cancer
      • Kidney Cancer
      • Brain Cancer
      • Musculo-skeletal cancers
    • Clinical Trials
    • Illuccix® & Gozellix®
    • Pipeline
    • Research & Innovation
  • Investor Centre
  • News & Views
  • Careers
    • Careers
    • Find a job
Header Image Frame Header Image Frame

Home News & Views

News & Views

News & Views

First Telix and Duchembio Joint Symposium – Emergence of PSMA-PET Imaging in South Korea

Events, News,

With our partner, Duchembio, we are pleased to present a first joint symposium on 68Ga-PSMA-PET prostate cancer imaging in…

Read more

NOBLE Study Brings Advanced Prostate Imaging to Rural Australia – First Patient Dosed

Clinical, News,

Telix is pleased to announce that the first Australian patient has been dosed in the international NOBLE Registry, a global study that aims to improve access for men to state-of-the-art…

Read more

ZIRCON Presentation at International Kidney Cancer Symposium 2021

Events, News,

Telix is pleased to release a poster on the Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab), the Company’s investigational imaging agent for clear cell renal cell carcinoma (ccRCC) with positron…

Read more

Australian TGA Approves Illuccix® for Prostate Cancer Imaging

ASX, News,

Australian Therapeutic Goods Administration has approved Illuccix® for the diagnostic imaging of men with prostate…

Read more

Telix Japan – Upcoming Events in November

Events, News,

We are pleased to announce Telix’s participation at three major industry events in Japan during November 2021….

Read more

Activities Report and Appendix 4C for September 2021 Quarter

ASX, News,

Telix provides its Appendix 4C and accompanying Activities Report for the quarter ended 30 September…

Read more

IPAX-1 Late Breaking Oral Presentation at the Congress of Neurological Surgeons (CNS) Meeting

Events, News,

Telix presented the IPAX-1 study of TLX101 in glioblastoma at the Congress of Neurological Surgeons Annual…

Read more

Telix Satellite Symposium at European Association of Nuclear Medicine Annual Congress 2021

Events, News,

Telix is pleased to announce a satellite symposium at the 34th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held from 20-23 October 2021….

Read more

First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer

Clinical, News,

Telix is pleased to announce that a first patient has been dosed in a Phase II study of TLX250-CDx (89Zr-DFO-girentuximab) in patients with triple-negative breast cancer (TNBC) at the Institut…

Read more

Telix Establishes Commercial Hub in Geneva, Switzerland

ASX, News,

Telix is pleased to announce that it has established a new commercial hub in Geneva through its subsidiary, Telix Pharmaceuticals (Switzerland)…

Read more
1 … 27 28 29 30 31 … 46

Subscribe

* indicates required

By subscribing, you are agreeing to the terms of our Global Privacy Policy and provide consent to receive updates from Telix”

Telix Pharmaceuticals Logo
  • Our Company
  • Contact
  • Our Portfolio
  • Careers
  • Investor Centre
  • News & Views

© Telix Pharmaceuticals Limited. 55 Flemington Road, North Melbourne, VIC 3051, Australia.

The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
This website is intended for corporate communication purposes only and is not intended as promotion or advertising to any audience in any country worldwide.

Privacy Policy. Terms of Use. Cookies Policy. Privacy Settings